An interventional study of controlling the MAP in Kidney Failure, Acute, sponsored by University Hospital, Ghent. Withdrawn at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-20.
Sponsored by University Hospital, Ghent · Not applicable, Interventional, and Treatment
The purpose of this study is to evaluate the renal perfusion depending on the MAP.
1,995 studies on the registry are indexed under Renal Insufficiency; 173 are open to participants now.
Browse Renal Insufficiency studies →University Hospital, Ghent is the lead sponsor of 665 studies on the registry; 156 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
creatinine clearance after 4 hours
resistance index
diuresis
urinary indices of renal function
This study is withdrawn, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Ghent